Cisen Pharmaceutical's subsidiary secures China's first generic approval for eye drop therapy

Stock News

Yesterday

Cisen Pharmaceutical Co.,Ltd. (SH: 603367) has announced that its subsidiary, Shandong Cisen Fodu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate from China's National Medical Products Administration for loteprednol etabonate and tobramycin eye drops.

The eye drops, classified as a Category 4 chemical drug, are designed to treat steroid-responsive ocular inflammation along with concurrent or potential bacterial infections of the eye surface. Fodu Pharmaceutical's initial registration application for loteprednol etabonate and tobramycin eye drops was accepted in 2025.

This approval marks the first generic version of the drug to be launched in the domestic Chinese market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/news/1115770895"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115770895\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115770895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 16:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115770895","market":"fut","top_or_hot":-1,"title":"Cisen Pharmaceutical's subsidiary secures China's first generic approval for eye drop therapy","media":"Stock News","content":"<p><b>Cisen Pharmaceutical Co.,Ltd.</b> (SH: 603367) has announced that its subsidiary, Shandong Cisen Fodu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate from China's National Medical Products Administration for loteprednol etabonate and tobramycin eye drops.<br><br>The eye drops, classified as a Category 4 chemical drug, are designed to treat steroid-responsive ocular inflammation along with concurrent or potential bacterial infections of the eye surface. Fodu Pharmaceutical's initial registration application for loteprednol etabonate and tobramycin eye drops was accepted in 2025.<br><br>This approval marks the first generic version of the drug to be launched in the domestic Chinese market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cisen Pharmaceutical's subsidiary secures China's first generic approval for eye drop therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCisen Pharmaceutical's subsidiary secures China's first generic approval for eye drop therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-14 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Cisen Pharmaceutical Co.,Ltd.</b> (SH: 603367) has announced that its subsidiary, Shandong Cisen Fodu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate from China's National Medical Products Administration for loteprednol etabonate and tobramycin eye drops.<br><br>The eye drops, classified as a Category 4 chemical drug, are designed to treat steroid-responsive ocular inflammation along with concurrent or potential bacterial infections of the eye surface. Fodu Pharmaceutical's initial registration application for loteprednol etabonate and tobramycin eye drops was accepted in 2025.<br><br>This approval marks the first generic version of the drug to be launched in the domestic Chinese market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603367","symbol_name":"辰欣药业","start_time":0,"source_url":"","article_id":"1115770895","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115770895","pubTimestamp":1789373299,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Cisen Pharmaceutical Co.,Ltd. (SH: 603367) has announced that its subsidiary, Shandong Cisen Fodu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate from China's National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603367":"辰欣药业","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF"},"translate_title":"慈森药业子公司获得中国首个滴眼液疗法仿制药批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603367":1,"IPOS":1},"content_text":"Cisen Pharmaceutical Co.,Ltd. (SH: 603367) has announced that its subsidiary, Shandong Cisen Fodu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate from China's National Medical Products Administration for loteprednol etabonate and tobramycin eye drops.The eye drops, classified as a Category 4 chemical drug, are designed to treat steroid-responsive ocular inflammation along with concurrent or potential bacterial infections of the eye surface. Fodu Pharmaceutical's initial registration application for loteprednol etabonate and tobramycin eye drops was accepted in 2025.This approval marks the first generic version of the drug to be launched in the domestic Chinese market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}